Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study
Publication date: 23–29 May 2015 Source:The Lancet, Volume 385, Issue 9982 Author(s): Lawrence Blonde , Johan Jendle , Jorge Gross , Vincent Woo , Honghua Jiang , Jessie L Fahrbach , Zvonko Milicevic Background For patients with type 2 diabetes who do not achieve target glycaemic control with conventional insulin treatment, advancing to a basal–bolus insulin regimen is often recommended. We aimed to compare the efficacy and safety of long-acting glucagon-like peptide-1 receptor agonist dulaglutide with that of insulin glargine, both combined with prandial insulin lispro, in patients with type 2 diabetes. M...
Source: The Lancet - May 23, 2015 Category: Journals (General) Source Type: research
[Articles] Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study
Dulaglutide in combination with lispro resulted in a significantly greater improvement in glycaemic control than did glargine and represents a new treatment option for patients unable to achieve glycaemic targets with conventional insulin treatment. (Source: LANCET)
Source: LANCET - May 22, 2015 Category: Journals (General) Authors: Lawrence Blonde, Johan Jendle, Jorge Gross, Vincent Woo, Honghua Jiang, Jessie L Fahrbach, Zvonko Milicevic Tags: Articles Source Type: research
Efficacy and Safety of LY2963016 Insulin Glargine Compared with Insulin Glargine (Lantus®) in Patients with Type 1 Diabetes in a Randomised Controlled Trial (The ELEMENT 1 Study)
ConclusionsBoth LY IGlar and IGlar, when used in combination with mealtime insulin lispro, provided effective and similar glucose control and similar safety profiles. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - May 15, 2015 Category: Endocrinology Authors: T.C. Blevins, D. Dahl, J. Rosenstock, L.L. Ilag, W.J. Huster, J.S. Zielonka, R.K. Pollom, M.J. Prince Tags: ORIGINAL ARTICLE Source Type: research
Diabetic pregnancy outcomes in mothers treated with basal insulin lispro protamine suspension or NPH insulin: a multicenter retrospective Italian study
The Journal of Maternal-Fetal & Neonatal Medicine, Ahead of Print. (Source: Journal of Maternal-Fetal and Neonatal Medicine)
Source: Journal of Maternal-Fetal and Neonatal Medicine - April 21, 2015 Category: Perinatology & Neonatology Tags: article Source Type: research
Individualizing treatment of type 2 diabetes by targeting postprandial or fasting hyperglycaemia: Response to a basal vs a premixed insulin regimen by HbA1c quartiles and ethnicity.
CONCLUSION: At baseline, the contribution of FHG to overall hyperglycaemia predominated at all HbA1c quartiles, whereas PHG was more clinically relevant at lower HbA1c levels and with a greater response to insulin lispro mix 25. Asians had a greater proportion of PHG and a lesser response to either insulins compared with Caucasians. Thus, responses to diabetes drugs by baseline HbA1c and ethnicity are worth investigating to better target and individualize treatment.
PMID: 25881510 [PubMed - as supplied by publisher] (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - April 13, 2015 Category: Endocrinology Authors: Scheen AJ, Schmitt H, Jiang HH, Ivanyi T Tags: Diabetes Metab Source Type: research
Glucose‐lowering effect and glycaemic variability of insulin glargine, insulin detemir and insulin lispro protamine in people with type 1 diabetes
ConclusionsThe results suggest that insulin lispro protamine and glargine are more effective than detemir in reducing glycaemic variability and improving glycaemic control in people with type 1 diabetes. Insulin lispro protamine seems to lead to fewer hypoglycaemic events than other insulin regimens. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - April 2, 2015 Category: Endocrinology Authors: G. Derosa, I. Franzetti, F. Querci, D. Romano, A. D'Angelo, P. Maffioli Tags: ORIGINAL ARTICLE Source Type: research
Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial
This study is registered with ClinicalTrials.gov, number NCT01175811. Findings Between Feb 7, 2011, and Nov 7, 2012, 402 patients were enrolled (199 in the premix group, 203 in the basal-bolus group) and 399 were included in the primary analysis (197 in the premix group, 202 in the basal-bolus group). HbA1c change at week 24 was −1·1% for both treatment groups. The least squares mean difference between groups in HbA1c change from baseline was 0% (95% CI −0·1 to 0·2). Insulin lispro mix was non-inferior to basal-bolus therapy based on the prespecified margin of 0·4%. The frequency of adverse events, and the incide...
Source: The Lancet Diabetes and Endocrinology - March 6, 2015 Category: Endocrinology Source Type: research
Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics
This article is protected by copyright. All rights reserved. (Source: Diabetes/Metabolism Research and Reviews)
Source: Diabetes/Metabolism Research and Reviews - March 1, 2015 Category: Endocrinology Authors: Paolo Pozzilli, Tadej Battelino, Thomas Danne, Roman Hovorka, Przemyslawa Jarosz‐Chobot, Eric Renard Tags: Review Article Source Type: research
A Comparison of Glide Force Characteristics Between 2 Prefilled Insulin Lispro Pens
Glide force, average glide force, and glide force variability of the insulin lispro 200 units/mL pen (Eli Lilly and Company, Indianapolis, IN, USA) were compared to the Humalog® KwikPen® 100 units/mL pen (hereafter, KwikPen; Eli Lilly and Company, Indianapolis, IN, USA). Data were collected on 2 doses, 2 injection speeds, and 2 needle types. Insulin lispro 200 units/mL pen showed significantly lower maximum glide force, average glide force, and glide force variability than the KwikPen across all combinations of dose size, dose speed, and needle type. The lower glide force observed with the insulin lispro 200 units/...
Source: Journal of Diabetes Science and Technology - February 27, 2015 Category: Endocrinology Authors: Rees, T. M., Lennartz, A. H., Ignaut, D. A. Tags: Technology Report Source Type: research
Adverse Drug Reaction reports for cardiometabolic drugs from sub‐Saharan Africa: A study in VigiBase
Conclusions‘In recent years the number of Adverse Drug Reactions (ADRs) reported in Sub Saharan Africa (SSA) has sharply increased. The data showed the well‐known population‐based differential ADR profile of ACE‐inhibitors in the SSA population.’This article is protected by copyright. All rights reserved. (Source: Tropical Medicine and International Health)
Source: Tropical Medicine and International Health - February 21, 2015 Category: Tropical Medicine Authors: Derbew Fikadu Berhe, Kristina Juhlin, Kristina Star, Kidanemariam G/Michael Beyene, Mukesh Dheda, Flora M Haaijer‐Ruskamp, Katja Taxis, Peter GM Mol Tags: Original Article Source Type: research
Glucose‐lowering effect and glycemic variability of insulin glargine, insulin detemir, and insulin lispro protamine in people with type 1 diabetes
Conclusionsinsulin lispro protamine and glargine seems to be more effective than detemir in reducing glycemic variability and improving glycemic control in people with type 1 diabetes. Insulin lispro protamine seems to give less hypoglycemic events than other insulin regimens. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - February 19, 2015 Category: Endocrinology Authors: Giuseppe Derosa, Ivano Franzetti, Fabrizio Querci, Davide Romano, Angela D'Angelo, Pamela Maffioli Tags: Original Paper Source Type: research
Clinical use and efficacy of biphasic insulin lispro 50/50 in people with insulin treated diabetes – a nationwide evaluation of clinical practice
Current Medical Research & Opinion, Ahead of Print. (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - February 9, 2015 Category: Research Tags: article Source Type: research
Isolation and Characterization of Acetylated Derivative of Recombinant Insulin Lispro Produced in Escherichia coli
Conclusions
The derivative of insulin lispro formed during biosynthesis of the drug was identified to be N-ε-acetyl-L-lysine (B31) insulin lispro. (Source: Pharmaceutical Research)
Source: Pharmaceutical Research - February 7, 2015 Category: Drugs & Pharmacology Source Type: research
Pharmacologic Management of Types 1 and 2 Diabetes Mellitus and Their Complications in Women of Childbearing Age
The numbers of women of childbearing age with pregestational diabetes mellitus (diabetes existing before pregnancy) are increasing, primarily because more patients are developing type 2 diabetes at younger ages. The teratogenicity associated with hyperglycemia in early pregnancy is well documented, and tight glucose control minimizes the risk of congenital malformation. Preconception planning is essential; thus contraception that does not worsen complications of diabetes is desirable. In addition, because contraceptives are not 100% effective, the treatment of elevated blood glucose levels, hypertension, and dyslipidemia i...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - February 3, 2015 Category: Drugs & Pharmacology Authors: Mimi S. Mukherjee, Valerie A. Coppenrath, Bree A. Dallinga Tags: Review of Therapeutics Source Type: research
Dulaglutide: The Newest GLP-1 Receptor Agonist for the Management of Type 2 Diabetes.
CONCLUSIONS: Dulaglutide is the fifth GLP-1 RA approved for T2D in the United States. It is an attractive option because it is dosed once-weekly, provides A1C lowering similar to liraglutide, weight reduction similar to exenatide, and has an adverse effect profile similar to exenatide and liraglutide.
PMID: 25565404 [PubMed - as supplied by publisher] (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - January 6, 2015 Category: Drugs & Pharmacology Authors: Thompson AM, Trujillo JM Tags: Ann Pharmacother Source Type: research
